Forbion European Acquisition Corp. (Nasdaq: FRBN) is a blank-check company sponsored by Forbion Capital Partners, a life-sciences-focused venture capital firm headquartered in the Netherlands. The SPAC completed its initial public offering in 2021, targeting acquisition opportunities within the European healthcare and life-sciences sector. The company filed an 8-K with the Securities and Exchange Commission on November 2, 2023, reflecting ongoing corporate activity as the vehicle progressed through its post-IPO timeline. Forbion Capital Partners brings significant domain expertise in biotechnology and medtech to its SPAC sponsorship, placing FRBN within a specialized cohort of healthcare-focused blank-check companies. Readers seeking the full filing history, deal timeline, and sponsor data for FRBN can sign up for complete access at SpacDesk.